UAUmit Aydogan

Umit Aydogan

*This is an algorithmically generated author record based on publicly available information.

Umit Aydogan has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of the brachial and the radial measurement values measured by the digital devices and mercury sphygmomanometer

    by Murat Çeliktepe, Oktay Sarı, Ümit Aydoğan, Özlem Ciğerli, Alper Sönmez, Bayram Koç

    • 22 September 2015
      • Vol. 33, S156-62

    Development of a medication adherence scale for familial Mediterranean fever (MASIF) in a cohort of Turkish children.

    by Sirzat Yesilkaya, Cengizhan Acikel, Berna Eren Fidanci, Adem Polat, Betül Sozeri, Nuray Aktay Ayaz, Balahan Bora Makay, Dogan Simsek, Nurver Akinci, Gul Özçelik, et al.

    To develop and assess the validity and reliability of an adherence scale concerning medical treatment in paediatric FMF patients. The Medication Adherence Scale in FMF Patients (MASIF) is a 18-item questionnaire that evaluates adherence to medication in four domains. Validation of the instrument was accomplished in paediatric FMF patients (aged 2-18 years) under medication at least for 6 months. The first step was to build up the scale through qualitative approach (with interviews using semi-structured questions). Validation analyses included assessment of feasibility, face and content validity; construct validity, internal consistency and test-retest reliability. One hundred and fifty patients with FMF were enrolled in the study. The mean age of the patients was 11.11±4.02 years and 48.7% of them were male. The MASIF was found to be feasible and valid for both face and content. It correlated with the Morisky Medication Adherence Scale as a gold standard thereby demonstrating good construct validity (r=0.515, p<0.001). Assessment of content validity identified four subscales. The internal consistency, Cronbach's alpha was 0.728. There was a positive and significant correlation between test and retest scores (r=0.843; p<0.001). Also, a significant correlation between parents' and children's reports (r=0.781, p<0.001). Based on these results, the use of this scale to assess and follow up the adherence to treatment in paediatric FMF patients under medical treatment is recommended.


  • Comparison of ambulatory blood pressure measurement with home, office and pharmacy measurements: is arterial blood pressure measured at pharmacy reliable?

    by Sinan Mutlu, Oktay Sari, Erol Arslan, Umit Aydogan, Yusuf C. Doganer, Bayram Koc

    Standardizing arterial blood pressure (BP) measurement is difficult because of different performers like doctor or pharmacy employee. We investigated the reliability between different BP measurement methods. The study was conducted in an internal medicine service with 160 patients in Ankara, Turkey. First, the subjects' BP was measured by doctor. Then, 24-hour BP monitoring devices were placed. Participants were then instructed to measure their BPs both at home and in pharmacy. The next day, arterial BP was measured by the doctor for the second time. The prevalence rates of masked and white coat hypertension were 8.8% (n = 14) and 8.1% (n = 13), respectively. There was no statistically significant differences between ambulatory measurement and home, office and pharmacy measurements (P > 0.05). The consistency rate between ambulatory and home measurements was 97.5% (kappa = 0.947, P < 0.001). The consistency rate between ambulatory and pharmacy measurements was 82.5% (kappa = 0.634, P < 0.001). When compared with ambulatory measurement, the most sensitive (98.0%) and most specific (96.8%) method was home measurement. There was a moderate positive correlation between ambulatory and other measurements in both systolic and diastolic values. There was a positive and very strong correlation between ambulatory and home measurements of systolic and diastolic ABP values (respectively; r = 0.926 and r = 0.968) and there was a statistically significant relation between these measurements (P < 0.001). The results of all measurement methods were close to each other. The most sensitive and specific method was home measurement when compared with ambulatory measurement. But both office and pharmacy measurements had also high sensitivity and specificity.


  • Blood pressure control in patients with hypertension: a retrospective cohort study

    by Umit Aydogan, Yusuf C. Doganer, Aslı Atik, James E. Rohrer, Deniz Engin Gok, Ebru Cirpan, Mahmut I. Yilmaz, Kenan Saglam

    Hypertension (HT) is prevalent in Turkey and even with pharmacological interventions HT control rates do not meet guideline recommendations. We aimed to estimate the proportion of hypertensive patients who achieved target blood pressure (BP) and seek to determine the predictors responsible for failure of to reach goals.We conducted a retrospective cohort study involving patients with HT. A total of 437 patients were identified with a current diagnosis of HT at baseline. All available predictors for BP improvements were included in the multivariate linear regression model.Follow-up data on HT goal achievements was available for 276 (63.1%) participants. Only 18.1% of the patients at the baseline visit, and 48.6% at the follow-up visit achieved the overall SBP/DBP targets specified by the JNC-8 guideline. Significant differences were determined by baseline and 1st visit measurements of mean SBP/DBP levels (P < 0.001, P < 0.001, respectively). DM and baseline SBP were positively associated with SBP improvement (β = 8.410, P = 0.003; β = 0.692, P < 0.001, respectively), whereas being prescribing more HT medications and being older were negatively associated with improvement (β = -7.968, P = 0.005; β = -5.707, P = 0.037; respectively). DM, baseline DBP and HT duration were positively associated with DBP improvement (β = 4.539, P = 0.012; β = 0.702, P < 0.001; β = 0.023, P = 0.012; respectively), whereas additional HT medications and GFR values were negatively associated with improvement (β = -5.682, P = 0.002; β = -0.098, P = 0.005; respectively).Although the progress in achieving in BP targets was encouraging, only half of patients had reached the HT goals. Adequate pharmacological approaches and comprehensive management strategies should be implemented in hypertensive patients.


  • Open Access

    Latex allergy symptoms and awareness of health care students

    by Ozgur Kartal, Oktay Sari, Mustafa Gulec, Mit Aydogan, Ugur Musabak, Osman Sener


  • Comparison of cystatin-C and pentraxin-3 in coronary atherosclerosis

    by Yusuf C. Doganer, Umit Aydogan, Mustafa Aparci, Polat Nerkiz, Cem Barcin, Tuncer Cayci, Oktay Sari

    Inflammation is one of the numerous factors that promote atherosclerosis. Cystatin-C (Cys-C) and pentraxin-3 (PTX-3) predominantly play roles in inflammation. Thus, we evaluated whether these markers were related to the presence and severity of coronary artery disease (CAD). Eighty-two stable patients who had undergone coronary angiography were enrolled in the study. Patients were diagnosed with significant (>50% stenosis) and nonsignificant (<50% stenosis) CAD. Patients with diabetes, chronic heart failure, chronic kidney disease, and so on were excluded from the study. Patients without CAD had higher Cys-C levels compared with those with CAD (1338.96±396.71 vs. 853.69±406.72 ng/ml, P<0.001). However, the PTX-3 level was inversely lower in patients without CAD (110.40±48.10 vs. 149.46±49.44 pg/ml, P=0.001). The Cys-C level was found to be 677.11±335.56, 1024.18±401.21, and 1338.96±396.71 ng/ml in patients with significant CAD and nonsignificant CAD, and healthy individuals, respectively (P<0.001). The PTX-3 level was inversely reduced in these groups: 168.43±49.09, 131.14±43.10, and 110.40±48.10 pg/ml, respectively (P<0.001). We observed that the levels of Cys-C and PTX-3 were inversely varied in the same study groups. These parameters may aid detection of the presence or identification of the severity of CAD when used in combination. Determinative values could exactly be described in the large study groups.


  • The effect of levothyroxine replacement therapy on lipid profile and oxidative stress parameters in patients with subclinical hypothyroid

    by Serkan Mutlu, Adem Parlak, Umit Aydogan, Aydogan Aydogdu, Bugra Soykut, Cemal Akay, Kenan Saglam, Abdullah Taslipinar

    The purpose of this present study is to investigate the levels of oxidative stress parameters in patients with subclinical hypothyroidism (SH) and the effects of levothyroxine (LT4) replacement therapy on these parameters and lipid profile. At the beginning of the study blood samples were collected from the patients in order to analyse oxidative stress parameters, lipid profile and biochemical markers. After replacement therapy with LT4, in the third month, same tests were performed again. At the baseline superoxide dismutase (SOD) levels were found to be higher in SH patients, compared to the euthyroid group. After LT4 therapy, statistically significant decreases in SOD and catalase levels and increase in HDL-C levels were noticed. LT4 treatment was found to have positive effects on oxidative stress indicators and HDL-C levels.


  • Distribution of psychiatric symptoms among young Turkish males and the relationship between these symptoms and socio-demographic characteristics

    by Umit Aydogan, Halil Akbulut, Ozcan Uzun, Servet Yuksel, Turker Turker, Orhan Gevrek, Serkan Mutlu, Polat Nerkiz, Oktay Sari, Cemil Celik, et al.

  • The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients

    by Adem Parlak, Atila Iyisoy, Umit Aydogan, Erdinc Cakir, Kenan Saglam


  • Open Access

    Elevated pentraxin-3 levels are related to blood pressure levels in hypertensive patients: an observational study

    by Adem Parlak, Umit Aydogan, Atila Iyisoy, Mehmet Aytug Dikililer, Altug Kut, Erdinc Cakir, Kenan Saglam

    In this study, relationship between systolic and diastolic blood pressure and pentraxin-3 (PTX3) levels in hypertensive patients was investigated. Overall, 80 patients with stage 1 hypertension between 40-61 years of age without any disease and 80 healthy volunteers were included to the study. Blood samples obtained to measure PTX3 levels and biochemical analysis. Relationship between PTX3 levels and clinical and biochemical parameters were analyzed using multivariate regression analysis. Although systolic and diastolic blood pressures were significant different, there were no differences regarding age and gender between hypertensives and normotensives. In each group, significant statistical differences were found between PTX3 and CRP levels (PTX3 (ng/mL) 35.25±5.45 and 0.27±0.24, p0.05). On multivariate regression analysis PTX3 was found to strongly affect blood pressure (beta=0.82, 95% CI 0.644-0.799, p<0.001, and beta=0.84, 95% CI 0.422-0.799, p<0.001, respectively for systolic and diastolic blood pressures), CRP and total cholesterol are found to affect moderately (beta=0.115-0.265, 95% CI 0.101-0.572, p<0.05 and beta=0.107-0.141, 95% CI 0.041-0.110, p<0.05, respectively). This study showed that PTX3 levels are higher in newly diagnosed hypertensive patients than in healthy individuals. In addition, it was noticed that increased PTX3 levels causes increase in systolic and diastolic blood pressures.